Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Kozminski

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Urology|June 25, 2014
Reply: To PMID 24958478Michael A Kozminski, Todd M Morgan
The Journal of Urology|January 24, 2012
A brief history of rejuvenation operationsMichael A Kozminski, David A Bloom
Journal of Natural Products|August 7, 2007
Distinctions among conifer exudates by proton magnetic resonance spectroscopyJoseph B Lambert, Michael A Kozminski, Jorge A Santiago-Blay
BJU International|May 15, 2014
Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)Michael A Kozminski, John T Wei, Jason Nelson, et al.
Journal of Natural Products|February 24, 2007
Proton nuclear magnetic resonance characterization of resins from the family pinaceaeJoseph B Lambert, Michael A Kozminski, Carl A Fahlstrom, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 20, 2010
How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatmentsMichael A Kozminski, Peter J Neumann, Eric S Nadler, et al.
Journal of Endourology|July 16, 2014
Symptomatic subcapsular and perinephric hematoma following ureteroscopic lithotripsy for renal calculiMichael A Kozminski, David J Kozminski, William W Roberts, et al.
Phytochemistry|July 23, 2013
Molecular classification of the natural exudates of the rosidsJoseph B Lambert, Eric W Donnelly, Eric A Heckenbach, et al.
Health Affairs (Project Hope)|April 12, 2012
In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survivalPeter A Ubel, Scott R Berry, Eric Nadler, et al.
Urologic Oncology|May 4, 2016
Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomyMichael A Kozminski, Scott Tomlins, Adam Cole, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Urology|June 25, 2014
Reply: To PMID 24958478Michael A Kozminski, Todd M Morgan
The Journal of Urology|January 24, 2012
A brief history of rejuvenation operationsMichael A Kozminski, David A Bloom
Journal of Natural Products|August 7, 2007
Distinctions among conifer exudates by proton magnetic resonance spectroscopyJoseph B Lambert, Michael A Kozminski, Jorge A Santiago-Blay
BJU International|May 15, 2014
Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)Michael A Kozminski, John T Wei, Jason Nelson, et al.
Journal of Natural Products|February 24, 2007
Proton nuclear magnetic resonance characterization of resins from the family pinaceaeJoseph B Lambert, Michael A Kozminski, Carl A Fahlstrom, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 20, 2010
How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatmentsMichael A Kozminski, Peter J Neumann, Eric S Nadler, et al.
Journal of Endourology|July 16, 2014
Symptomatic subcapsular and perinephric hematoma following ureteroscopic lithotripsy for renal calculiMichael A Kozminski, David J Kozminski, William W Roberts, et al.
Phytochemistry|July 23, 2013
Molecular classification of the natural exudates of the rosidsJoseph B Lambert, Eric W Donnelly, Eric A Heckenbach, et al.
Health Affairs (Project Hope)|April 12, 2012
In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survivalPeter A Ubel, Scott R Berry, Eric Nadler, et al.
Urologic Oncology|May 4, 2016
Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomyMichael A Kozminski, Scott Tomlins, Adam Cole, et al.
Pageof 2